At the same time, currently, inhibition of transforming growth factor beta (TGF-β) is considered one of the promising approaches, whose crucial role in the development of pulmonary fibrosis has been repeatedly confirmed, both in experimental and clinical studies [13], as well as the suppression of some other growth factors, including vascular endothelial growth factors (VEGFR-1, VEGFR-2, and VEGFR-3), fibroblast growth factors (FGFR-1, FGFR-2, and FGFR-3), and platelet growth factors (PDGFR-α and PDGFR-β) (Table 1) [14]. The gene discussed is VEGFA; the disease is pulmonary fibrosis.